
|Videos|February 12, 2015
The Optimal Use of Cabazitaxel for Prostate Cancer
Author(s)Christopher Sweeney, MBBS
Christopher Sweeney, MBBS, medical oncologist, Dana-Farber Cancer Institute, discusses the optimal use of cabazitaxel for the treatment of prostate cancer.
Advertisement
Clinical Pearls
Christopher Sweeney, MBBS, medical oncologist, Dana-Farber Cancer Institute, discusses the optimal use of cabazitaxel for the treatment of prostate cancer.
- More oncologists are becoming comfortable with using the cytotoxic chemotherapy cabazitaxel. It is only approved for use after docetaxel.
- After prescribing docetaxel to a patient with hormone-sensitive disease, a physician can then choose to administer docetaxel again or switch to cabazitaxel.
- Sequencing of abiraterone, enzalutamide, cabazitaxel, docetaxel, sipuleucel-T, and radium-223 is not entirely clear.
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Dr Cloughesy on Extended Follow-Up Data for Vorasidenib in IDH1/2 Mutant Glioma
2
Bispecific ADC Iza-Bren Extends Survival in Advanced TNBC
3
ASCO 2026 GU Cancer Highlights: Beyond the LBAs
4
FDA Grants Priority Review to Giredestrant for ER+/HER2- Breast Cancer
5



































